Company Overview and News
BOCA RATON, Fla., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Q.E.P. Co., Inc. (OTC: QEPC.PK) announced today that it has entered into a definitive asset purchase agreement to acquire the hard surface and carpet tile distribution business of the Kraus Group of Companies (the “Transaction”). The Kraus Group of Companies is seeking approval of the Transaction under the Companies Creditor’s Arrangement Act in Canada and the United States Bankruptcy Court.
BOCA RATON, Fla., July 23, 2018 (GLOBE NEWSWIRE) -- Q.E.P. Co., Inc. (OTC:QEPC.PK) (the "Company") announced today that its Board of Directors has expanded the executive leadership team by appointing Harry Schulman as Chief Executive Officer, effective August 1, 2018, reporting to Lewis Gould, who will continue as Executive Chairman of the Company’s Board of Directors. Mr. Schulman will also continue as a member of the Company’s Board of Directors.
First Quarter Net Sales – $87.9 Million First Quarter Net Income – $1.4 Million First Quarter Earnings Per Share (Diluted) – $0.44
BOCA RATON, Fla., April 04, 2018 (GLOBE NEWSWIRE) -- Q.E.P. Co., Inc. (OTC:QEPC.PK) (the "Company" or “QEP”) announced today the expansion of its operations in Australia through the acquisition of certain assets of PR Floors Pty Ltd. (“PR Floors”). PR Floors is a wholesale flooring distribution company established in Queensland in 1961 that provides a wide range of branded flooring products, underlays, marine sealants and accessories as well as one of the most extensive ranges of flooring tools and accessories in the country.
BOCA RATON, Fla., April 03, 2018 (GLOBE NEWSWIRE) -- Q.E.P. Co., Inc. (OTC:QEPC.PK) (the "Company") announced today that it has expanded the Board of Directors from six to seven directors and has elected a new Board member, Harry D. Schulman. He will attend the Company’s next Board meeting.
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to QEPC / Q.E.P. Co., Inc. on message board site Silicon Investor.
|A cheap stock...QEPC.||A cheap stock...QEPC.||A cheap stock...QEPC.|
as of ET